miR-146a经TLR4/MyD88途径加速巨噬细胞迁移所致动脉硬化的作用机制

doi:10.6040/j.issn.1671-7554.0.2021.0162

摘要/Abstract

摘要： 目的探讨微小RNA-146a(miR-146a)经Toll样受体4(TLR4)/髓系分化因子88蛋白(MyD88)途径调控巨噬细胞迁移所致动脉硬化的具体机制。方法 RAW264.7巨噬细胞分为空白组、ox-LDL组、miR-146a mimic组、miR-146a inhibitor组、shRNA-MyD88组、shRNA-NC组、shRNA-MyD88+miR-146a mimic组、shRNA-MyD88+miR-146a inhibitor组,除空白组,其他各组均用50 mg/L ox-LDL进行干预;采用Western blotting法检测TLR4、MyD88、核因子κB(NF-κB)、白细胞介素-6(IL-6)蛋白表达水平。采用qPCR法检测miR-146a、TLR4、MyD88、NF-κB、IL-6基因表达水平。采用Transwell法检测巨噬细胞迁移能力。结果 (1)ox-LDL组细胞内TLR4、IL-6蛋白含量及巨噬细胞迁移率均高于空白组(P均<0.01),miR-146a低于空白组(P<0.01);(2)miR-146a mimic组细胞TLR4 mRNA相对表达量及蛋白含量、巨噬细胞迁移率低于ox-LDL组,miR-146a mRNA相对表达量高于ox-LDL组(P均<0.01);miR-146a inhibitor组细胞TLR4 mRNA相对表达量及蛋白含量、巨噬细胞迁移率高于ox-LDL组,miR-146a mRNA相对表达量低于ox-LDL组(P均<0.01);(3)shRNA-MyD88组MyD88、NF-κB、IL-6蛋白含量、巨噬细胞迁移率低于ox-LDL组(P<0.01),miR-146a、TLR4表达无明显差异(P>0.05);shRNA-MyD88+miR-146a mimic组miR-146a表达高于shRNA-MyD88组,TLR4蛋白含量低于shRNA-MyD88组(P<0.01),MyD88、NF-κB、IL-6蛋白含量表达、巨噬细胞迁移率与shRNA-MyD88组无明显差异(P>0.05);shRNA-MyD88+miR-146a inhibitor组miR-146a表达低于shRNA-MyD88组,TLR4蛋白含量表达高于shRNA-MyD88组(P<0.01),MyD88、NF-κB、IL-6蛋白含量表达、巨噬细胞迁移率与shRNA-MyD88组无明显差异(P>0.05)。结论 miR-146a是动脉粥样硬化的保护性因子,通过拮抗TLR4/MyD88途径调控炎症因子分泌进而抑制巨噬细胞迁移所致动脉粥样硬化进程,为动脉粥样硬化的防治提供新的治疗靶点。

关键词: 微小RNA-146a, Toll样受体4, 炎症反应, 动脉粥样硬化, 巨噬细胞迁移

Abstract: Objective To explore the specific mechanism of microRNA-146a(miR-146a)regulating macrophage migration induced arteriosclerosis via toll-like receptor 4(TLR4)and myeloid differentiation factor88(MyD88)pathway(TLR4/MyD88). Methods RAW264.7 macrophages were divided into blank group, ox-LDL group, miR-146a mimic group, miR-146a inhibitor group, siRNA-MyD88 group, siRNA-NC group, siRNA-MyD88+miR-146a mimic group, and siRNA-MyD88+miR-146a inhibitor group. Except the blank group, the other groups were treated with 50mg/L ox-LDL. The protein expressions of TLR4, MyD88, nuclear factor kappa-B(NF-κB), and interleukin-6(IL-6)were detected with Western blotting. The mRNA expressions of miR-146a, TLR4, MyD88, NF-κB and IL-6 were detected with qPCR. The migration ability of macrophages was detected with Transwell assay. Results (1) The ox-LDL group had higher protein expressions of TLR4 and IL-6, but lower migration ability of macrophages and lower mRNA expression of TLR4 than the blank group(P<0.01). (2) The miR-146a mimic group had lower mRNA and protein expressions of TLR4, lower migration ability of macrophages, but higher mRNA expression of miR-146a than the ox-LDL group(P<0.01). The miR-146a inhibitor group had higher mRNA and protein expressions of TLR4, higher migration ability of macrophages, but lower mRNA expression of miR-146a than the ox-LDL group(all P<0.01). (3) The shRNA-MyD88 group had lower protein expressions of MyD88, NF-κB and IL-6, and lower migration ability of macrophages than the ox-LDL group(P<0.01); there was no difference in the expressions of miR-146a and TLR4(P>0.05). The shRNA-MyD88+miR-146a mimic group had higher expression of miR-146a but lower expression of TLR4 than the shRNA-MyD88 group(P<0.01). There were no significant differences in the protein expressions of MyD88, NF-κB, IL-6 and migration rate of macrophages between shRNA-MyD88 group and shRNA-MyD88 group(P>0.05). The shRNA-MyD88+miR-146a inhibitor group had lower expression of miR-146a but higher expression of TLR4 than the shRNA-MyD88 group(P<0.01). There were no significant differences in the expressions of MyD88, NF-κB, IL-6 and migration rate of macrophages(P>0.05). Conclusion miR-146a is a protective factor of atherosclerosis, which can inhibit the process of macrophage migration by regulating the secretion of inflammatory factors by antagonizing TLR4/MyD88 pathway. This can provide a new therapeutic target for the prevention and treatment of arteriosclerosis.

Key words: miR-146a, Toll-like receptor 4, Inflammatory response, Arteriosclerosis, Macrophage migration

中图分类号:

R543.5

杨佳,张曼,陈凯明,曹曦. miR-146a经TLR4/MyD88途径加速巨噬细胞迁移所致动脉硬化的作用机制[J]. 山东大学学报 (医学版), 2021, 59(11): 1-7.

YANG Jia, ZHANG Man, CHEN Kaiming, CAO Xi. Mechanism of miR-146a accelerating macrophage migration induced arteriosclerosis via TLR4/MyD88 pathway[J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 1-7.

参考文献

[1] Taleb S. Inflammation in atherosclerosis [J]. Arch Cardiovasc Dis, 2016, 109(12): 708-715.
[2] Gliozzi M, Scicchitano M, Bosco F, et al. Modulation of nitric oxide synthases by oxidized LDLs: role in vascular inflammation and atherosclerosis development [J]. Int J Mol Sci, 2019, 20(13): 3294-3295.
[3] Qu RN, Qu W. Metformin inhibits LPS-induced inflammatory response in VSMCs by regulating TLR4 and PPAR-γ [J]. Eur Rev Med Pharmacol Sci, 2019, 23(11): 4988-4995.
[4] Carpi S, Scoditti E, Massaro M, et al. The extra-virgin olive oil polyphenols oleocanthal and oleacein counteract inflammation-related gene and miRNA expression in adipocytes by attenuating NF-κB activation [J]. Nutrients, 2019, 11(12): 2855-2856.
[5] Poznyak A, Grechko AV, Poggio P, et al. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation [J]. Int J Mol Sci, 2020, 21(5): 1835.
[6] Shi ZG, Sun Y, Wang KS, et al. Effects of miR-26a/miR-146a/miR-31 on airway inflammation of asthma mice and asthma children [J]. Eur Rev Med Pharmacol Sci, 2019, 23(12): 5432-5440.
[7] 王文俏, 刘露, 许馨, 等. miR-146a/b在动脉粥样硬化疾病中的研究进展[J]. 生命科学, 2015, 27(4): 471-476.
[8] Ganju A, Khan S, Hafeez BB, et al. miRNA nanotherapeutics for cancer [J]. Drug Discov Today, 2017, 22(2): 424-432.
[9] 王文俏, 刘露, 许馨, 等. miR-146a/b在动脉粥样硬化疾病中的研究进展[J]. 生命科学, 2015, 27(4): 471-476.
[10] Mellis D, Caporali A. MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target [J]. Biochem Soc Trans, 2018, 46(1): 11-21.
[11] Wang H, Li X, Li T, et al. Multiple roles of microRNA-146a in immune responses and hepatocellular carcinoma [J]. Oncol Lett, 2019, 18(5): 5033-5042.
[12] Bai Y, Li Z, Liu W, et al. Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway [J]. Acta Cir Bras, 2019, 34(11): e201901104.
[13] Wang XP, Luoreng ZM, Zan LS, et al. Bovine miR-146a regulates inflammatory cytokines of bovine mammary epithelial cells via targeting the TRAF6 gene [J]. Dairy Sci, 2017, 100(9): 7648-7658.
[14] Gong J, Li J, Dong H, et al. Inhibitory effects of berberine on proinflammatory M1 macrophage polarization through interfering with the interaction between TLR4 and MyD88 [J]. BMC Complement Altern Med, 2019, 19(1): 314.

相关文章 15

[1]	段盈竹,董波,于睿. 内在情感与类风湿关节炎患者冠状动脉粥样硬化风险关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2026, 64(4): 63-71.
[2]	李习平,邱梅,黄瑞峰,林慧慧,刘丝丝,罗鸿莹,王宇月,王敏,杨晓彤. 基于脂质沉积抑制-代谢清除协同效应的黄连素抗动脉粥样硬化机制研究进展[J]. 山东大学学报 (医学版), 2025, 63(9): 77-83.
[3]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[4]	杜艾家,张曼,陈鹤,王丽新,尚应殊. 微小RNA-1270靶向调控血管生成素样蛋白7抑制巨噬细胞炎症和脂质蓄积[J]. 山东大学学报 (医学版), 2025, 63(2): 1-9.
[5]	沈海涛,乔亚琴,董萍,路燕. Toll样受体4调控的程序性坏死和铁死亡对对乙酰氨基酚肝损伤的影响[J]. 山东大学学报 (医学版), 2024, 62(4): 1-8.
[6]	许天旗,常娜,张帅,李莎,矫秉轩,于鑫鑫,王锡明. 非酒精性脂肪肝识别基于CTA颈动脉高危斑块[J]. 山东大学学报 (医学版), 2023, 61(12): 36-43.
[7]	杨元凤,熊高才,黎豫川,罗玉玲,张敬杰. 鹿苓安肾颗粒对慢性肾功能衰竭大鼠炎症反应及细胞凋亡的影响[J]. 山东大学学报 (医学版), 2023, 61(10): 9-16.
[8]	吴虹,张正铎,唐延金,祁少俊,高希宝. 5-甲基四氢叶酸对大鼠动脉粥样硬化的潜在干预作用[J]. 山东大学学报 (医学版), 2022, 60(8): 6-13.
[9]	李锐,石存现,于翠翠. 右美托咪定对30例体外循环患者肠道屏障损伤的影响[J]. 山东大学学报 (医学版), 2022, 60(7): 83-88.
[10]	谢佳莹,祁佳,宋铭,李育林,王迪,贾旭,张薇,钟明,尚嫄嫄. 血清蛋白质β-折叠水平与冠心病的相关性[J]. 山东大学学报 (医学版), 2022, 60(1): 21-26.
[11]	周溪,黄霂晗,任玉洁,邱洋. 新型冠状病毒感染与天然免疫及炎症反应[J]. 山东大学学报 (医学版), 2021, 59(5): 15-21.
[12]	闵傲雪,朱天瑞,张凤,王冉冉,李晓红. A151对糖氧剥夺和脂多糖诱导的BV-2细胞极化的影响[J]. 山东大学学报 (医学版), 2021, 59(3): 1-9.
[13]	高金梅,黄映波,冯珍珍. 单核细胞趋化蛋白-1对67例全身炎症反应综合征患者的诊断价值[J]. 山东大学学报 (医学版), 2021, 59(10): 77-81.
[14]	付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24-31.
[15]	金海燕,张炎,马小莉,韩羽,赵蕙琛,刘元涛,张玉超. MiR-122与miR-33a在2型糖尿病合并冠心病患者中的表达[J]. 山东大学学报 (医学版), 2020, 58(3): 94-98.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed